Compare EXK & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EXK | LQDA |
|---|---|---|
| Founded | 1981 | 2004 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.1B |
| IPO Year | 2004 | 2020 |
| Metric | EXK | LQDA |
|---|---|---|
| Price | $10.27 | $39.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $13.94 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 8.7M | 964.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $63.94 | $278.87 |
| Revenue Next Year | $8.76 | $57.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $3.23 | $11.85 |
| 52 Week High | $15.15 | $46.67 |
| Indicator | EXK | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 55.54 |
| Support Level | $8.33 | $31.75 |
| Resistance Level | $10.31 | $46.67 |
| Average True Range (ATR) | 0.54 | 2.01 |
| MACD | 0.18 | 0.27 |
| Stochastic Oscillator | 80.59 | 62.95 |
Endeavour Silver Corp is a Canadian mineral company engaged in the evaluation, acquisition, exploration, development, and exploitation of precious metal properties in Mexico and Chile. The Company has three operating mining segments namely; Guanacevi and Terronera in Mexico, and Minera Kolpa in Peru. The company has one development project in Mexico, Terronera, as well as Exploration and Corporate segments. The Exploration segment consists of projects in the exploration and evaluation phases in Mexico, Chile, and the USA.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.